-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Flavopiridol Hydrochloride
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/131740-09-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 131740-09-5 |
| Description | Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. |
Product Information
| Synonyms | NSC 649890 HCl; NSC649890 HCl; NSC-649890 HCl |
| Molecular Weight | 438.3 |
| Molecular Formula | C21H20ClNO5.HCl |
| Canonical SMILES | CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl |
| InChI | InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3;1H/t12-,17+;/m0./s1 |
| InChIKey | LGMSNQNWOCSPIK-LWHGMNCYSA-N |
| Boiling Point | 603.6°C at 760 mmHg |
| Melting Point | 169.5-170°C |
| Flash Point | 318.8°C |
| Purity | >98% |
| Solubility | In Vitro: H2O : ≥ 20 mg/mL(45.63 mM) DMF : 7.69 mg/mL(17.55 mM;Need ultrasonic) |
| Appearance | Light yellow to khaki (Solid) |
| Storage | 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture) |
| Complexity | 628 |
| Exact Mass | 437.0796782 |
| In Vitro | Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream Caspases. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopirido. |
| PSA | 94.14000 |
| Target | CDK; Autophagy; HIV |
| Vapor Pressure | 2.03E-15mmHg at 25°C |
